Peginterferon alfa-2a
Also known as: PEG-IFN alfa-2a, PEG‑IFNα‑2a, Pegasys, pegylated interferon alfa-2a, pegylated interferon alfa‑2a, RO-25-8310
Source Peginterferon alfa-2a at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peginterferon alfa-2a (Pegasys) is a pegylated type I interferon approved for chronic hepatitis C and used off‑label for hepatitis D and certain myeloproliferative neoplasms. The polyethylene glycol (PEG) attachment prolongs its circulation, allowing once‑weekly subcutaneous injection and providing antiviral and immunomodulatory activity that can lower viral load and modify disease course.
Mechanism of Action
Peginterferon alfa‑2a binds the interferon‑α/β receptor (IFNAR) on target cells, triggering the JAK‑STAT pathway and inducing expression of antiviral, antiproliferative, and immunoregulatory genes. The 40 kDa PEG moiety increases molecular size, slowing absorption, extending the half‑life to about 50 hours, limiting renal clearance, and reducing immunogenicity, which together sustain biological activity longer than non‑pegylated interferon‑α.
What the Research Shows
Pharmacokinetic studies show peginterferon alfa‑2a has a 50‑hour absorption half‑life, a restricted volume of distribution and >100‑fold lower renal clearance versus conventional interferon‑α, explaining its once‑weekly dosing. In chronic hepatitis C, peginterferon alfa‑2a monotherapy yields better virologic responses than non‑pegylated forms, and combination with ribavirin (or telaprevir) markedly improves sustained virological response rates. A phase 2b trial in chronic hepatitis D demonstrated that adding peginterferon alfa‑2a to bulevirtide increased the proportion of patients with undetectable HDV RNA (46 % vs 12 % with bulevirtide alone). Reviews of myeloproliferative neoplasms cite peginterferon alfa‑2a as a disease‑modifying option for polycythemia vera, essential thrombocythemia, and primary myelofibrosis, though long‑term comparative data remain limited.
Reported Benefits
Pegylation permits once‑weekly subcutaneous injection and sustains antiviral activity, improving patient convenience. In hepatitis C, peginterferon alfa‑2a combined with ribavirin (or direct‑acting antivirals) raises cure‑related response rates compared with ribavirin alone. In hepatitis D, adding peginterferon to bulevirtide more than triples the rate of undetectable viral RNA versus bulevirtide monotherapy. In myeloproliferative neoplasms, peginterferon alfa‑2a offers a non‑chemotherapy disease‑modifying alternative that can reduce mutant allele burden.
Limitations of the Evidence
Peginterferon alfa‑2a does not cure hepatitis C and its benefit depends on combination therapy. Direct head‑to‑head trials comparing alfa‑2a with alfa‑2b are lacking. Evidence for hepatitis D efficacy comes from a single phase 2b study with modest sample size, and long‑term outcomes are unknown. In myeloproliferative neoplasms, data are largely from reviews and observational experience; randomized trials are needed to define optimal dosing and comparative effectiveness. Hematologic toxicities limit use in some patients.
Safety Considerations
Common adverse effects include hematologic abnormalities such as leukopenia, neutropenia, and thrombocytopenia, which were the most frequent events in the hepatitis D trial. Overall tolerability is comparable to non‑pegylated interferon, but pegylated forms still cause flu‑like symptoms, fatigue, and depression. Regular blood‑count monitoring is advised, and dose adjustments may be required for significant cytopenias. Caution is warranted in patients with pre‑existing bone‑marrow suppression or autoimmune disorders.
How It Is Administered
Peginterferon alfa‑2a is administered by subcutaneous injection, typically once weekly due to its prolonged half‑life conferred by PEG attachment. Formulations are supplied as pre‑filled syringes or vials for injection. No oral or intravenous routes are described in the cited literature.
Routes of Administration
Goals & Uses
- Chronic Hepatitis C treatmentAntiviralHigh
- Essential thrombocythemia controlHematologicModerate
- Chronic Hepatitis B treatmentAntiviralHigh
- ImmunomodulationImmunologyModerate
- Antineoplastic (melanoma, renal cell carcinoma)OncologyLow
- Chronic hepatitis B suppressionAntiviralHigh
- Chronic hepatitis C eradicationAntiviralHigh
Contraindications
- Severe psychiatric disorders (e.g., severe depression with suicidal ideation)NeuropsychiatricHigh
- Severe autoimmune diseaseImmunologicalHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Neonates and Infants (benzyl alcohol-containing formulations)PediatricHigh
- Pregnancy (when used with ribavirin)ReproductiveHigh
- Known hypersensitivity to interferon alfa or PEG componentsAllergic/ImmunologicHigh
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Decompensated hepatic disease (Child-Pugh B/C)HepaticHigh
- Uncontrolled depressionPsychiatricModerate
Adverse Effects
- Flu-like symptoms (fatigue, fever, myalgia, headache)ConstitutionalCommon
- Hematologic toxicity (neutropenia, thrombocytopenia, anemia)HematologicCommon
- Neuropsychiatric effects (depression, irritability, insomnia, suicidality)NeuropsychiatricCommon
- Injection site reactionsLocalCommon
- Retinopathy / Optic neuropathyOphthalmologicUncommon
- Thyroid dysfunction (hypothyroidism or hyperthyroidism)EndocrineUncommon
- Flu‑like syndromeSystemicCommon
- Thyroid dysfunctionEndocrineUncommon
- NeutropeniaHematologicCommonLow neutrophil count
- DepressionPsychiatricUncommon
- Injection‑site reactionLocalCommon
Drug Interactions
- AzathioprineHigh
- Theophylline / MethylxanthinesModerate
- TelbivudineHigh
- RibavirinModerate
- CorticosteroidsModerate
- MethadoneModerate
- Myelosuppressive agents (e.g., azathioprine, hydroxyurea)High
Population Constraints
- PregnancyReproductive SafetyRelative
- Elderly (≥75 y)AgeRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Patients with pre-existing psychiatric disordersPsychiatricRelative
- Pediatric patients (<5 years)PediatricRelative
- Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
- Patients with pre-existing cardiac diseaseCardiovascularRelative
Regulatory Status
- European UnionApprovedApproved: Chronic hepatitis C, Chronic hepatitis B, Essential thrombocythemiaEMA approved; same brand name.
- United StatesApprovedApproved: Chronic hepatitis C, Chronic hepatitis B, Essential thrombocythemiaFDA approved as Pegasys®.
- United KingdomApprovedApproved: Chronic hepatitis C, Chronic hepatitis B, Essential thrombocythemiaMHRA approval aligned with EU status.
Approved by FDA (US) as Pegasys® for hepatitis C, hepatitis B, and essential thrombocythemia; also approved in EU and UK. Patent held by Roche.
Evidence & Sources
- Journal ArticleModerateBaker DE2001-01-01T00:00:00.000000Z
- Journal ArticleModerateAsselah T, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateZeuzem S, Welsch C, Herrmann E2003-01-01T00:00:00.000000Z
- Journal ArticleModerateVachhani P, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateLiapakis AM, Jacobson I2012-01-01T00:00:00.000000Z
Frequently Asked Questions
What diseases is peginterferon alfa‑2a officially approved to treat?
It is approved as a prescription medication for chronic hepatitis C. It is also used off‑label for chronic hepatitis D and for certain myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
How does pegylation change the dosing schedule compared with regular interferon‑α?
Pegylation increases the molecule’s size, slowing absorption and reducing renal clearance, which extends the half‑life to roughly 50 hours. This allows peginterferon alfa‑2a to be given once weekly instead of the more frequent dosing required for non‑pegylated interferon‑α.
What are the most common side effects patients should be monitored for?
The most frequently reported adverse events are hematologic, including leukopenia, neutropenia, and thrombocytopenia. Flu‑like symptoms, fatigue, and mood changes also occur. Regular blood‑count monitoring is recommended to detect cytopenias early.
Is peginterferon alfa‑2a effective for hepatitis D?
In a phase 2b trial, peginterferon alfa‑2a combined with bulevirtide achieved a 46 % undetectable HDV RNA rate at 24 weeks post‑treatment, significantly higher than bulevirtide alone (12 %). This suggests added benefit, though data are limited to this single study.
Can peginterferon alfa‑2a be used to treat blood cancers?
Reviews indicate peginterferon alfa‑2a is recommended for disease‑modifying therapy in myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. While promising, further clinical trials are needed to fully establish its efficacy and optimal use in these conditions.
What is Peginterferon alfa-2a?
Peginterferon alfa-2a (Pegasys) is a pegylated type I interferon approved for chronic hepatitis C and used off‑label for hepatitis D and certain myeloproliferative neoplasms. The polyethylene glycol (PEG) attachment prolongs its circulation, allowing once‑weekly subcutaneous injection and providing antiviral and immunomodulatory activity that can lower viral load and modify disease course.
What is Peginterferon alfa-2a used for?
Peginterferon alfa-2a is educationally associated with: Chronic Hepatitis C treatment, Essential thrombocythemia control, Chronic Hepatitis B treatment, Immunomodulation, Antineoplastic (melanoma, renal cell carcinoma), Chronic hepatitis B suppression, Chronic hepatitis C eradication. Educational only — not medical advice.
How is Peginterferon alfa-2a administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Peginterferon alfa-2a?
Reported adverse effects include: Flu-like symptoms (fatigue, fever, myalgia, headache), Hematologic toxicity (neutropenia, thrombocytopenia, anemia), Neuropsychiatric effects (depression, irritability, insomnia, suicidality), Injection site reactions, Retinopathy / Optic neuropathy, Thyroid dysfunction (hypothyroidism or hyperthyroidism), Flu‑like syndrome, Thyroid dysfunction, Neutropenia, Depression, Injection‑site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peginterferon alfa-2a?
Recorded contraindications: Severe psychiatric disorders (e.g., severe depression with suicidal ideation), Severe autoimmune disease, Pregnancy, Neonates and Infants (benzyl alcohol-containing formulations), Pregnancy (when used with ribavirin), Known hypersensitivity to interferon alfa or PEG components, Autoimmune hepatitis, Decompensated hepatic disease (Child-Pugh B/C), Uncontrolled depression. Consult a qualified clinician before use.